CellSeed Inc. Financial Summary for the Third Quarter of the Fiscal Year Ending December 2026〔Japanese GAAP〕(Non-consolidated)

Overview of Performance

This financial summary reports the financial results for the third quarter of the fiscal year ending December 2026. Net sales were 42,422 thousand yen (decrease Year-over-Year), operating loss was 834,147 thousand yen, ordinary loss was 835,701 thousand yen, and quarterly net loss was 910,077 thousand yen. By segment, the regenerative medicine support business recorded net sales of 37,944 thousand yen and an operating loss of 100,725 thousand yen, while the cell sheet regenerative medicine business recorded net sales of 4,477 thousand yen and an operating loss of 541,950 thousand yen, with deficits continuing in both segments. The full-year earnings guidance has been revised and disclosed. The exercise of the 25th series of stock acquisition rights has increased capital stock and capital surplus, indicating an improving capital structure; however, uncertainties remain regarding the company's ability to continue as a going concern.

Financial Position and Outlook

Total assets at the end of the third quarter were 1,819,030 thousand yen and net assets were 1,524,313 thousand yen, and an increase in cash and deposits led to a judgment that the financial base is stable. However, there remain uncertainties regarding early commercialization of the first regenerative medicine product, and future fundraising and partnership initiatives will be important. The financial summary notes that a revision to the earnings guidance for the fiscal year ending December 2026 has been disclosed, and results could change significantly depending on market conditions and R&D progress.